My groups’ primary research interests are in the genomics and molecular pathology of pancreatic cancer and the development of oncolytic virotherapy.
Our research aims to improve the efficacy of standard of care immunotherapy, chemotherapy and radiotherapy in human solid cancers by understanding the molecular mechanisms underlying tumour stromal contributions to tumour growth and therapy efficacy.
I study the biology of tumour invasion with a particular focus on the roles of the adhesion molecules expressed on the cell surface that mediate this process. Our group concentrates on the study of integrins that are the principal family of adhesion molecules that mediate the interaction between cells and the extracellular matrix.
My group’s work focuses on the role of the tumour suppressor protein LIMD1 and its family members Ajuba and WTIP and how their deregulation in normal tissue contributes to the development of lung, renal and breast cancer.
Our group investigates cancer evolution, with a focus on understanding how genetic changes influence disease progression, response to therapy and development of resistance. We particularly concentrate on gastrointestinal cancers such as colorectal, stomach and oesophageal cancer.
My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
My research interests focus on improving the care of women with breast cancer through clinical trials. I am investigating a variety of novel agents that target specific pathways within cancer cells and the surrounding tissue.